Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

89%

8 of 9 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 1

4(44.4%)

Phase 3

3(33.3%)

Phase 4

1(11.1%)

Phase 2

1(11.1%)

9Total

Phase 1(4)

Phase 3(3)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07739589Phase 4Completed

A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

Role: collaborator

NCT02158572Phase 3Completed

Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System

Role: lead

NCT01422135Phase 1Completed

Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females

Role: lead

NCT01375946Phase 1Completed

Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers

Role: lead

NCT01250210Phase 2Completed

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

Role: lead

NCT01181479Phase 3Completed

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

Role: lead

NCT01243580Phase 1Completed

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

Role: lead

NCT01623466Phase 1Completed

Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches

Role: lead

NCT01236768Phase 3Completed

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

Role: lead

All 9 trials loaded